dasiglucagon + placebo + GlucaGen HypoKit
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hypoglycemia
Conditions
Hypoglycemia
Trial Timeline
Sep 28, 2018 → Jun 28, 2019
NCT ID
NCT03667053About dasiglucagon + placebo + GlucaGen HypoKit
dasiglucagon + placebo + GlucaGen HypoKit is a phase 3 stage product being developed by Zealand Pharma for Hypoglycemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03667053. Target conditions include Hypoglycemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03667053 | Phase 3 | Completed |
Competing Products
20 competing products in Hypoglycemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MBX 1416 (INN imapextide) | MBX Biosciences | Phase 2 | 47 |
| MBX 1416 (Part A) + MBX 1416 (Part B) + Placebo + MBX 1416 (Part C) | MBX Biosciences | Phase 1 | 28 |
| Nasal Glucagon | Eli Lilly | Phase 3 | 77 |
| Glucagon + Insulin | Abvance Therapeutics | Phase 1 | 25 |
| Nasal Glucagon + Intramuscular Glucagon | Eli Lilly | Phase 1 | 33 |
| Nasal Glucagon 1 mg + Nasal Glucagon 2 mg + SC Glucagon + Nasal Glucagon 3 mg | Eli Lilly | Phase 2 | 52 |
| Nasal Glucagon | Eli Lilly | Phase 3 | 77 |
| Eplerenone + Placebo | Johnson & Johnson | Pre-clinical | 23 |
| Sitagliptin phosphate + Placebo | Merck | Approved | 85 |
| Pasireotide | Novartis | Phase 1 | 33 |
| Dasiglucagon | Novo Nordisk | Phase 3 | 76 |
| Glucagen + Mayne Glucagon | Pfizer | Phase 1 | 32 |
| Pramlintide | Bristol Myers Squibb | Approved | 84 |
| Dasiglucagon + Placebo | Zealand Pharma | Phase 1 | 30 |
| Dasiglucagon + Dasiglucagon + Placebo | Zealand Pharma | Phase 2 | 49 |
| ZP4207 + Glucagon | Zealand Pharma | Phase 1 | 30 |
| ZP4207 + Placebo | Zealand Pharma | Phase 1 | 30 |
| Dasiglucagon + Placebo | Zealand Pharma | Phase 3 | 74 |
| dasiglucagon + GlucaGen | Zealand Pharma | Phase 3 | 74 |
| Dasiglucagon + Placebo | Zealand Pharma | Phase 2 | 49 |